Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies

Mazyar Shadman

Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies

Reading

9 Dec 2024

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study

Reading

9 Dec 2024

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: Results from the phase 1 CaDAnCe-101 study

Reading

9 Dec 2024

Sameh Gaballa

Patient medication preferences in follicular lymphoma (FL) in the United States (USA): A discrete choice experiment (DCE)

Reading

9 Dec 2024

Judith Trotman

Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: Growth modulation index analysis from ROSEWOOD study

Reading

9 Dec 2024